Xylozolin 1 mg/ml, neusspray, oplossing

Xylozolin 1 mg/ml, neusspray, oplossing
Werkzame stof(fen)Xylometazoline
Toelatingslandnl
VergunninghouderPharmachemie
ATC-codeR01AA07
Farmacologische groepenDecongestiva en andere nasale preparaten voor lokaal gebruik

Patiëntenbijsluiter

Wat is het en waarvoor wordt het gebruikt?

{(Invented) name strength pharmaceutical form} contains the active ingredient xylometazoline, which is a topical decongestant that relieves nasal congestion. A decongestant reduces the swelling of the nasal mucosa.

{(Invented) name strength pharmaceutical form} is used for temporary symptomatic treatment of nasal congestion due to rhinitis or sinusitis.

{(Invented) name 0.5 mg/ml pharmaceutical form} is intended for children between 2 and 10 years of age.

{(Invented) name 1 mg/ml pharmaceutical form} is intended for adults as well as for children 10 years of age and older.

Wat moet u weten voordat u het gebruikt?

Do NOT use {(Invented) name strength pharmaceutical form}

  • if you are allergic (hypersensitive) to xylometazoline or any of the other ingredients of {(Invented) name strength pharmaceutical form} (see section 6).
  • if you have recently had neurosurgery (transsphenoidal hypophysectomy or other surgery exposing the meninx)
  • if you suffer from dry rhinitis (a form of chronic rhinitis that causes dry inflammation of the nasal mucous membrane with formation of crusts).

{(Invented) name 0.5 mg/ml pharmaceutical form}

  • in children younger than 2 years of age. {(Invented) name 1 mg/ml pharmaceutical form}
  • in children below 10 years of age.

Take special care with {(Invented) name strength pharmaceutical form}

Ask your doctor for advice:

  • if you are being treated with certain drugs for depression known as monoamine oxidase inhibitors (MAO inhibitors) or other medicinal products that may increase blood pressure.
  • if you suffer from coronary heart disease or high blood pressure.
  • if you suffer from an adrenal tumor (phaeochromocytoma).
  • if you suffer from metabolic disorders such as thyroid hyperfunction (hyperthyroidism), or diabetes
  • if you have an enlarged prostate.
  • if you suffer from porphyria (a metabolic disorder that affects the skin and/or nervous system).
  • if you suffer from increased pressure inside the eye, particularly narrow-angle glaucoma. Direct contact with the eyes should be avoided.

Long-term use of Xylometazoline nasal spray (longer than 7 days) may lead to chronic swelling and ultimately to the wasting away of the nasal mucous membrane (tissue inside the nose).

Use in children

{(Invented) name 0.5 mg/ml pharmaceutical form}

{(Invented) name 0.5 mg/ml pharmaceutical form} must not be used in infants, toddlers and children below 2 years of age.

{(Invented) name 1 mg/ml pharmaceutical form}

{(Invented) name 1 mg/ml pharmaceutical form} must not be used by children younger than 10 years of age.

Taking/Using other medicines

Please tell your doctor or pharmacist if you are taking/using or have recently taken/used any other medicines, including medicines obtained without a prescription.

Combined use of {(Invented) name strength pharmaceutical form} and certain drugs for depression (MAO inhibitors of the tranylcypromine type or tricyclic antidepressants) as well as high blood pressure (hypertension) medications can lead to a rise in blood pressure.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

Since the safety of use of {(Invented) name strength pharmaceutical form} during pregnancy and breast- feeding has not been sufficiently documented, you may use {(Invented) name strength pharmaceutical form} only upon the recommendation of your doctor and only after a careful risk-benefit evaluation. As overdosing may affect the blood supply to the unborn child or lead to a reduction of milk production, the recommended dose must not be exceeded during pregnancy and breast-feeding.

Driving and using machines

This medicine should not affect your ability to drive or operate machinery.

Hoe wordt het gebruikt?

Always use {(Invented) name strength pharmaceutical form} exactly as directed in this package leaflet. You should check with your doctor or pharmacist if you are not sure.

{(Invented) name 0.5 mg/ml pharmaceutical form}

Unless otherwise prescribed by your doctor, the usual dose in children between 2 and 10 years of age is 1 spray of {(Invented) name 0.5 mg/ml pharmaceutical form} into each nostril, according to need, but up to a maximum of 3 times daily.

{(Invented) name 1 mg/ml pharmaceutical form}

Unless otherwise prescribed by your doctor, the usual dose in adults and children 10 years of age and older is 1-2 sprays of {(Invented) name 1 mg/ml pharmaceutical form} into each nostril, according to need, but up to a maximum of 3 times daily.

Method of administration

After removing the protective cap, insert the spray aperture into the nostril and activate the pump once. Breathe gently through the nose during the spray procedure. After use, carefully wipe the nozzle with a clean paper tissue and replace the protective cap.

Notes:

Before the first use - and after interruption of treatment of more than 15 days - activate the pump several times until an even spray mist emerges. For subsequent applications, the metered-dose spray is ready for immediate use.

Before application of the nasal spray gently blow your nose. It is recommended to take the last dose of each day before you go to bed.

For hygienic reasons and to avoid infections, each spray bottle should only be used by the same person.

Duration of use

{(Invented) name strength pharmaceutical form} must not be used for longer than 7 days, unless prescribed by your doctor.

An interval of several days should elapse before re-administering the product.

When used to treat chronic rhinitis, the nasal spray may only be administered under medical observation, due to the risk of nasal mucosal atrophy (the wasting away of the skin inside the nose).

If you think the effect of {(Invented) name strength pharmaceutical form} is too weak or too strong, talk to your doctor or pharmacist.

If you use more {(Invented) name strength pharmaceutical form} than you should

In cases of significant overdose or accidental intake, in both children and adults, you must tell your doctor immediately. Monitoring and treatment in a hospital are necessary.

The following effects can occur:

  • dilated or constricted pupils
  • feeling sick (nausea) and vomiting
  • pallor, blue colouration of skin and lips
  • fever, sweating or also fall in body temperature
  • heart circulation problems, such as a heartbeat that is too slow, too fast, or irregular, rise or fall in blood pressure
  • suspension of breathing (apnoea)
  • lethargy, drowsiness and coma
  • anxiety, excitation, hallucinations and fits (convulsions).

Particularly in children, overdose can frequently be followed by convulsions and coma, slow heart rate, suspension of breathing (apnoea) and a rise in blood pressure, which can be followed by a fall in blood pressure.

If you forget to use {(Invented) name strength pharmaceutical form}

Do not take a double dose to make up for a forgotten dose, but continue to use as described in the dosage instructions.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Wat zijn mogelijke bijwerkingen?

Like all medicines {(Invented) name strength pharmaceutical form} can cause side effects, although not everybody gets them.

The following frequency conventions are used in the evaluation of side effects:

Very common affects more than 1 user in 10
Common 1 to 10 users in 100
Uncommon 1 to 10 users in 1,000
Rare 1 to 10 users in 10,000
Very rare less than 1 user in 10,000
Not known Frequency cannot be estimated from available data

Common

  • slight temporary irritation symptoms such as stinging or dryness of the nasal mucosa (tissue inside the nose) and/or throat.
  • sneezing

Uncommon

  • hypersensitivity reactions (skin rash, itching, swelling of skin and and mucous membranes)
  • after the effect has subsided increased sensation of a “blocked” nose
  • nosebleed

Rare

  • feeling your heart beat (palpitations)
  • increased heart rate
  • increase in blood pressure
  • feeling sick (nausea)

Very rare

  • nervousness (restlessness)
  • difficulty falling or staying asleep (insomnia)
  • sleepiness/drowsiness (mainly in children)
  • headache
  • dizziness
  • hallucinations or fits (mainly in children)
  • irregular heart beat
  • stop breathing (apnoea) in infants and neonates

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Verdere informatie

What {(Invented) name strength pharmaceutical form} contains

  • The active substance is xylometazoline hydrochloride. {(Invented) name 0.5 mg/ml pharmaceutical form} One spray (equivalent to 0.09 ml solution) contains 0.045 mg xylometazoline hydrochloride. {(Invented) name 1 mg/ml pharmaceutical form} One spray (equivalent to 0.09 ml solution) contains 0.09 mg xylometazoline hydrochloride.
  • The other ingredients are: citric acid monohydrate, sodium citrate dihydrate, glycerol 85%, water for injections.

What {(Invented) name strength pharmaceutical form} looks like and contents of the pack

{(Invented) name 0.5 mg/ml pharmaceutical form} is a clear, almost colourless solution available in a brown glass bottle containing 10 ml (not less than 90 actuations) or 2x10 ml (not less than 2x90 actuations) of solution sealed with a spray pump with a nose adapter and a protecting cap.

{(Invented) name 1 mg/ml pharmaceutical form} is a clear, almost colourless solution available in a brown glass bottle containing 10 ml (not less than 90 actuations), 15 ml (not less than 135 actuations) or 2x10 ml (not less than 2x90 actuations) of solution sealed with a spray pump with a nose adapter and a protecting cap.

< Not all pack sizes may be marketed >

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Pharmachemie BV

Swensweg 5

2031 GA Haarlem

Manufacturer

Merckle GmbH

Ludwig-Merckle-Straße 3

89143 Blaubeuren

Duitsland

Pharmachemie B.V.

Swensweg 5

2031 GA Haarlem

Nederland

Teva Czech Industries s.r.o. Ostravska 29, c.p. 305 74770 Opava-Komarov

Tsjechië

Teva Operations Poland Sp. z o.o. ul. Mogilska 80. 31-546, Krakow

Polen

Teva Operations Poland Sp. z o.o

Ul. Sienkiewicza 25. 99-300, Kutno

Polen

In het register ingeschreven onder  
Xylozolin 0,5 mg/ml, neusspray, oplossing: RVG 109042.
Xylozolin 1 mg/ml, neusspray, oplossing: RVG 109043.

This medicinal product is authorised in the Member States of the EEA under the following names:

<to be completed nationally>

This leaflet was last approved in September 2012.

Version:

R07

Laatst bijgewerkt op 24.08.2023

Meer medicijnen met dezelfde werkzame stof

De volgende medicijnen bevatten ook de werkzame stof Xylometazoline. Raadpleeg uw arts over een mogelijk alternatief voor Xylozolin 1 mg/ml, neusspray, oplossing

Medicijn
Vergunninghouder

Logo

Uw persoonlijke medicatie-assistent

Medicijnen

Blader hier door onze uitgebreide database van A-Z medicijnen, met effecten, bijwerkingen en doseringen.

Stoffen

Alle actieve ingrediënten met hun werking, toepassing en bijwerkingen, evenals de medicijnen waarin ze zijn opgenomen.

Ziekten

Symptomen, oorzaken en behandeling van veelvoorkomende ziekten en verwondingen.

De weergegeven inhoud vervangt niet de originele bijsluiter van het medicijn, vooral niet met betrekking tot de dosering en werking van de afzonderlijke producten. We kunnen geen aansprakelijkheid aanvaarden voor de nauwkeurigheid van de gegevens, omdat deze gedeeltelijk automatisch zijn omgezet. Raadpleeg altijd een arts voor diagnoses en andere gezondheidsvragen.

© medikamio